Market Overview

Cowen Suspends PTC Therapeutics Target, Puts Rating Under Review

Share:
Related PTCT
Watch These 8 Huge Call Purchases In Wednesday Trade
18 Biggest Mid-Day Gainers For Monday
Early-stage study data on Catabasis Pharma's Duchenne candidate edasalonexent published; shares ahead 12% premarket (Seeking Alpha)

Cowen’s Ritu Baral put the prior Outperform rating for PTC Therapeutics, Inc. (NASDAQ: PTCT) under review, while suspending the previous $120 price target, after the company announced it had not been able to agree with German reimbursement authorities on price and may have to withdraw the Translarna™ [Ataluren] drug from the German market.

Currently, Germany is the only region in which the drug has been commercially launched. The recent development creates significant uncertainly around the EU commercial opportunity, analyst Ritu Baral said.

Related Link: Sanofi In Talks To Buy PTC Therapeutics

She wrote further, “This jeopardizes our entire EU valuation of Translarna, given Germany’s position as the largest market in the EU as well as the process of reference pricing, which normally suggests that prices in Germany are among the highest in Europe.”

PTC Therapeutics has also received a refuse-to-file from the FDA on its Translarna DMD NDA. “We do not think that the agency rejection of the application was for benign or administrative reasons…As a result, our valuation of Translarna in the US is also in question,” Baral mentioned.

Latest Ratings for PTCT

DateFirmActionFromTo
Nov 2016Credit SuisseUpgradesNeutralOutperform
Nov 2016CitigroupUpgradesNeutralBuy
Aug 2016CitigroupMaintainsNeutral

View More Analyst Ratings for PTCT
View the Latest Analyst Ratings

Posted-In: Cowen Ritu BaralAnalyst Color Health Care Analyst Ratings General

 

Related Articles (PTCT)

View Comments and Join the Discussion!